Because several receptor tyrosine kinases can activate the same downstream pathways (PI3K/AKT and RAS/MAPK), the therapeutic effect of blocking a particular tyrosine kinase receptor is reduced when tumour cells driver activation of the downstream pathways through alternative TKRs [132,133]. The gene discussed is NTRK1; the disease is neoplasm.